Tetra Bio-Pharma and Santé Cannabis Announce Completion of the First Phase 2 Cannabis Oil Trial in Cancer and Non-Cancer Patients

by NASDAQ Market News March 4, 2019

NASDAQ Market News
Click here to email author

ContraFect Announces $6.94 Million in Funding from CARB-X to Support Development of Amurin Platform Against All Gram-negative ESKAPE Pathogens

Orion Group Financial Statement documents 2018 and Corporate Governance Statement published

Ads